AstraZeneca finds early-stage success with MET inhibitor in lung cancer - BioPharma Dive

AstraZeneca finds early-stage success with MET inhibitor in lung cancer  BioPharma Dive

AstraZeneca and Chi-Med's investigational MET inhibitor gave lung cancer patients additional benefit when used in combination with the British pharma's EFGR ...



Comments

Popular posts from this blog

Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic ...

Stage 4 Lung Cancer Life Expectancy

A Review of the Etiology and Epidemiology of Bladder Cancer: All ...